Dovitinib-RIBOTAC (TFA)

Dovitinib RIBOTAC TFA is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC TFA can inhibit the metastasis of breast cancer and has anti-tumor activity[1].

Product Specifications

CAS Number

[2759351-69-2]

UNSPSC

12352005

Target

DNA/RNA Synthesis; PPAR; Programmed Cell Death 4 (PDCD4) ; PROTACs

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; PROTAC; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dovitinib-ribotac-tfa.html

Purity

98.35

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C(C2=NC3=CC(N4CCN(CCNC(NCCOCCOCCOCCOC5=C(O)C=C(/C=C6C(C(C(OCC)=O)=C(NC7=CC=CC=C7)S/6)=O)C=C5)=O)CC4)=CC=C3N2)=C(N)C8=C(C=CC=C8F)N1.OC(C(F)(F)F)=O

Molecular Formula

C53H57F4N9O12S

Molecular Weight

1120.13

References & Citations

[1]Zhang P, et al. Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. J Am Chem Soc. 2021 Aug 25;143 (33) :13044-13055.